No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19

BACKGROUND: The use of hydroxychloroquine (HCQ), with or without concurrent administration of azithromycin (AZM), for treatment of COVID-19 has received considerable attention. The purpose of this study was to determine whether HCQ administration is associated with improved mortality in COVID-19 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sands, Kenneth, Wenzel, Richard, McLean, Laura, Korwek, Kimberly, Roach, Jonathon, Miller, Karla, Poland, Russell E., Burgess, L. Hayley, Jackson, Edmund, Perlin, Jonathan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834474/
https://www.ncbi.nlm.nih.gov/pubmed/33359949
http://dx.doi.org/10.1016/j.ijid.2020.12.060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834474/
https://www.ncbi.nlm.nih.gov/pubmed/33359949
http://dx.doi.org/10.1016/j.ijid.2020.12.060

Ejemplares similares